Treatment of chronic liver disease caused by 3β-hydroxy-Δ5-C27-steroid dehydrogenase deficiency with chenodeoxycholic acid

H Ichimiya, H Nazer, T Gunasekaran, P Clayton, J Sjövall

Abstract
Deficiency of 3β-hydroxy-Δ5-C27-steroid dehydrogenase, the second enzyme in the sequence that catalyses the synthesis of bile acids from cholesterol, leads to chronic liver disease in childhood as well as to malabsorption of fat and fat soluble vitamins. A 4 year old boy with this condition has been successfully treated by oral administration of a bile acid—chenodeoxycholic acid. He had been jaundiced since birth, grew poorly because of rickets, and had severe pruritus. Plasma transaminase activities were persistently raised. Chenodeoxycholic acid 125 mg twice daily for two months, and then 125 mg daily, cured his jaundice and pruritus, returned his transaminase activities to normal, and eliminated the need for calcitriol for prevention of rickets. On this treatment he has so far remained well for two years. A diagnosis of 3β-hydroxy-Δ5-C27-steroid dehydrogenase deficiency should be considered in any child with unexplained chronic hepatitis or cirrhosis, especially if the liver disease is accompanied by a clinically obvious malabsorption of fat soluble vitamins. A simple colorimetric test of the urine confirms the diagnosis and effective treatment can be started.

In the principal pathway for the synthesis of chenodeoxycholic acid and cholic acid from cholesterol in the liver (fig 1), the first (and rate limiting) step is catalysed by cholesterol 7α-hydroxylase. 7α-Hydroxycholesterol is then converted to 7α-hydroxy-cholesterol-4-en-3-one by a 3β-hydroxy-Δ5-C27-steroid dehydrogenase/isomerase. This enzyme was shown to be deficient in the cultured fibroblasts of a boy from Saudi Arabia who was one of three siblings who had chronic cholestatic liver disease. When first studied at the age of 3 months, the patient had undetectable concentrations of chenodeoxycholic acid and cholic acid in his plasma despite clear evidence of cholestasis. Instead of synthesising the usual primary bile acids, he was producing large amounts of 3β, 7α-dihydroxy-5-choleenoic acid and 3β, 7α, 12α-trihydroxy-5-choleenoic acid—that is, bile acids formed from precursors in which normal conversion of the 3β-hydroxy-Δ5 structure to a 3α-hydroxy-5β (H) structure had not occurred. The unsaturated bile acids were present at high concentration in the urine in sulphated form. They did not seem to be able to promote bile acid dependent bile flow and the absorption of fat and fat soluble vitamins from the intestine. The infant had conjugated hyperbilirubinaemia from birth, steatorrhoea, and low plasma concentrations of vitamins A, D, and E. There was also evidence that either the production of abnormal bile acids or the failure to produce cholic and chenodeoxycholic acids was causing progressive liver damage. The patient had raised transaminase activities and liver biopsy specimens taken from his affected siblings showed a giant cell hepatitis that progressed to a micronodular cirrhosis.

We argued that if this patient were given chenodeoxycholic acid or cholic acid, or both, these bile acids would be retained within the entero-hepatic circulation and could promote bile acid dependent bile flow and facilitate micellar solubilisation of fats and fat soluble vitamins. As cholesterol 7α-hydroxylase is inhibited by cholic and chenodeoxycholic acids, we could also hope for a reduction in the synthesis of abnormal metabolites of 7α-hydroxycholesterol. This report describes the progress of this patient who was not treated until the age of 4·3 years, at which time he was started on treatment with chenodeoxycholic acid.

Case report
The family history and the initial presentation of this patient have previously been described.
He was lost to follow up but then presented at the King Faisal Specialist Hospital and Research Centre, Riyadh at the age of 2·8 years. A variable degree of jaundice had persisted since infancy with dark urine and stools that were pale or yellow. He had severe pruritus, had retarded growth, and did not walk until the age of 2 years. His parents had noted bowing of his legs. On examination his weight was 13·6 kg (25th centile), height 82·5 cm (below the 3rd centile), and head circumference 50·5 cm (50th centile). Growth failure was associated with clinical rickets, with widening of wrists and a rachitic rosary in addition to his bowed legs. His liver was palpable 4 cm from the right costal margin and was firm. The spleen was not palpable.

Investigation confirmed persistent jaundice, hepatic dysfunction and vitamin D malabsorption. The plasma bilirubin concentration was 41 μmol/l (direct 36 μmol/l); alanine aminotransferase activity 56 IU/l (reference range 10–25); aspartate aminotransferase activity 57 IU/l (reference range 10–40); and alkaline phosphatase activity 1085 IU/l (reference range 100–300). The albumin concentration was 47 g/l and prothrombin time and partial thromboplastin time normal. Calcium concentration was 1·67 mmol/l (reference range 2·13–2·62) and phosphate concentration 1·36 mmol/l (reference range 1·29–1·78). Radiography of the wrist showed florid rickets. Ultrasound scan of the liver confirmed that it was enlarged, with normal echogenicity.

Between the ages of 2·8 and 4·3 years he was treated with supplements of fat soluble vitamins. The vitamin D was given as the 1,25-dihydroxy derivative (calcitriol, 0·5 μg/day). His rickets improved clinically, radiologically, and biochemically (calcium concentration 1·67 mmol/l, alkaline phosphatase activity 300 IU/l). The jaundice and raised transaminase activities persisted, however (fig 2). Chenodeoxycholic acid was undetectable in plasma (as it had been at 3 months) but some cholic acid was present in both plasma (<4·3 μmol/l) and in bile.

At the age of 4·3 years, treatment with chenodeoxycholic acid (Chendol, Weddel) was started, initially in a dose of 125 mg (one capsule) twice daily (18 mg/kg/day), reducing to 125 mg daily after two months. At the time of writing treatment has continued for two years. After the first two months he was already feeling better. He was more active and his appetite had improved. The pruritus had disappeared and his urine had become normal in colour. The size of the liver was unchanged. His plasma bilirubin concentration had fallen within the reference range for the first time in his life and the transaminase activities were almost normal (alanine aminotransferase 35 and aspartate aminotransferase 44 IU/l). The improvement was maintained over the ensuing months (fig 2) and he had no problem with diarrhoea as a result of the chenodeoxycholic acid treatment.

By the age of 5·3 years, he had achieved considerable catch up growth. His weight was 19·2 kg (50th centile) and height 105 cm (above 10th centile) but limb deformities as a result of his previous rickets were still evident and he had carious teeth. The liver was palpable 5 cm from the costal margin (span 8·5 cm). Bilirubin concentration and transaminase activities were all within the reference ranges. His serum cholesterol concentration was normal (4·86 mmol/l).

Plasma chenodeoxycholic acid concentration was 1·6 μmol/l, which is within the physiologic reference range. Skeletal radiographs confirmed complete healing of the rickets. Plasma 25-hydroxyvitamin D and vitamin E concentrations were at the upper limit of the reference range when his dietary intake was supplemented with 800 units of vitamin D and 200 mg of α-tocopherol acetate daily. The vitamin D supplement was subsequently reduced to 240 units daily and the alkaline phosphatase activity has remained normal.

**Discussion**

Without permission to do a liver biopsy it was difficult to estimate the extent of our patient’s liver disease at the age of 4 years. It seemed unlikely that it was as severe as that of his brother, who had an established micronodular cirrhosis by the age of 3·8 years. The index case had no signs of portal hypertension and plasma albumin concentration and clotting times were normal. The bilirubin concentration and transaminase activities, though persistently raised, were slightly lower than they had been at the age of 3 months. It would seem therefore that liver disease in siblings with 3β-hydroxy-Δ5-
Treatment of chronic liver disease caused by 3β-hydroxy-Δ5-C27-steroid dehydrogenase deficiency with chenodeoxycholic acid

C27-steroid dehydrogenase deficiency may progress at different rates. This may be related to the degree of synthesis of normal bile acids that occurs in the different siblings. In the absence of the normal 3β-hydroxy-Δ5-C27-steroid dehydrogenase enzyme, oxidation of 7α-hydroxycholesterol or 3β-hydroxy-Δ5 bile acids might be catalysed by hepatic 3β-hydroxy-Δ5-steroid dehydrogenases not normally concerned in bile acid synthesis, or by similar enzymes in the gut flora. In the case of our patient, some glycocholic acid was found in bile—as much as 30% of the total C24 bile acids at the age of 4-3 years.

Our index case had severe pruritus. The concentration of cholic acid in his plasma was <4-3 μmol/l (which is within the reference range) and chenodeoxycholic acid was undetectable. We must conclude, therefore, that pruritus can be caused either by bile acids with a 3β-hydroxy-Δ5 structure, or by the accumulation of something else than bile acids in patients with cholestasis.

Our patient continued to have severe malabsorption of vitamin D until treatment with bile acids was started. Treatment of his rickets required the use of calcitriol which, unlike dietary vitamin D, can be absorbed directly into the portal circulation.

The rationale for treatment with bile acids has been given in the introduction to this paper. To create a normal pool of bile salts it would have been necessary to give both cholic and chenodeoxycholic acid; cholic acid is not readily available for therapeutic use. On the other hand, chenodeoxycholic acid and ursodeoxycholic acid are extensively used to treat gall stones. Chenodeoxycholic acid is also effective in the treatment of another inborn error of bile acid synthesis, cerebrotendinous xanthomatosis, in which the aim of treatment is to give enough bile acid to inhibit cholesterol 7α-hydroxylase and hence reduce the synthesis of bile alcohols from cholesterol. Ursodeoxycholic acid does not inhibit cholesterol 7α-hydroxylase, or suppress the production of abnormal metabolites in cerebrotendinous xanthomatosis. We wanted to suppress the synthesis of abnormal metabolites and so chenodeoxycholic acid seemed the best choice. Chenodeoxycholic acid has, however, some hepatotoxic properties when used in patients with gall stones, and is also considered to contribute to the damage to hepatocytes that occurs in patients with cholestasis. Thus before starting treatment with chenodeoxycholic acid we confirmed that concentrations of chenodeoxycholic acid were low in both bile and in blood, and during treatment we ensured that plasma concentrations did not rise above the physiological range.

The choice of dose of chenodeoxycholic acid that we used was somewhat empirical and based partly on the fact that 125 mg capsules are readily available. We estimated that a 4 year old boy with a normal pool of bile acids should synthesise and lose in the faeces about 3 mg/kg/day of bile acids and so this was the minimum dose. The dose of chenodeoxycholic acid used in adults for dissolution of gall stones and for suppression of abnormal metabolite synthesis in cerebrotendinous xanthomatosis is about 12-5 mg/kg/day. Patients with cerebrotendinous xanthomatosis have some endogenous chenodeoxycholic acid synthesis and we felt that a higher dose may be required for our patient. Thus, treatment at the dose of two capsules (15 mg/kg/day) was chosen, reducing to one capsule when there was no longer any biochemical evidence of cholestasis.

Clinically the benefit of chenodeoxycholic acid was evident within two weeks. The bilirubin concentration was normal within four weeks, and the aspartate transaminase activity by three months. This meant that we had a baseline of normal liver function tests against which to look for possible long term toxicity of chenodeoxycholic acid but none has been detected during almost two years.

In addition to the possible toxic effects of chenodeoxycholic acid, we had two other concerns about the treatment. The first was that if high doses of vitamin D were given, and absorption of fat soluble vitamins was stimulated by producing effective intestinal bile salt concentrations, our patient might develop the effects of hypervitaminosis D. Thus the calcitriol was discontinued before starting chenodeoxycholic acid, and a modest vitamin D supplement (800 units) was given. On this regimen no hypercalcaemia was detected and plasma 25-hydroxyvitamin D remained within the reference range.

To avoid hypervitaminosis A, high doses of vitamin A were also avoided during treatment with chenodeoxycholic acid.

A second cause of concern was the possibility of raised serum concentrations of cholesterol during treatment with bile acids. Catabolism to bile acids is an important way of eliminating cholesterol. Treatment with chenodeoxycholic acid should reduce cholesterol catabolism by inhibiting cholesterol 7α-hydroxylase. The treatment may cause an increase in the synthesis of bile acids from cholesterol in the gut and these two mechanisms might together contribute to a rise in serum cholesterol concentration. While receiving treatment our patient’s serum cholesterol concentration was within the reference range.

The success of treatment with chenodeoxycholic acid in 3β-hydroxy-Δ5-C27-steroid dehydrogenase deficiency makes it important that this diagnosis be considered in any child with chronic hepatitis particularly if it is accompanied by fat soluble vitamin malabsorption. The diagnosis can be made in any clinical chemistry laboratory by a colorimetric test on the urine (the Lifschütz reaction) and it can then be confirmed by fast atom bombardment mass spectrometry or gas chromatography/mass spectrometry in specialised centres. If the latter methods are used to screen for inborn errors of bile acid metabolism, patients with reduced activity of 3-oxo-Δ4-steroid 5β-reductase (the third enzyme in the sequence leading from cholesterol to chenodeoxycholic acid) will also be detected because the urine contains characteristic 3-oxo-Δ4 bile acids. We would not advocate the use of chenodeoxycholic acid in these patients without careful assessment for a number of reasons.
Firstly, the patient may not have a primary defect of 3-oxo-Δ4-steroid 5β-reductase but some other disease such as fumaryl acetoacetase deficiency. Secondly, plasma concentrations of chenodeoxycholic acid in these patients are usually considerably increased. It is likely that concentrations in hepatocytes are also increased and this may be damaging.

Thirdly, experience has shown that chenodeoxycholic acid can be harmful. Giving chenodeoxycholic acid to one infant excreting 3-oxo-Δ4 bile acids in his urine aggravated his cholestasis and transaminase activity increased (H Nazer, T Gunasekaran, J Sjövall, unpublished observations). Bilirubin concentration and transaminase activities then returned to pretreatment measurements when chenodeoxycholic acid was withdrawn.